老虎證券
Invest
Pricing
Rewards
Support
Learn
About
Quotes
TigerAI
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
杭州先為達生物科技股份有限公司(臨時代碼)
成交量:
- -
成交額:
- -
市值:
- -
市盈率:
- -
高:
- -
開:
- -
低:
- -
收:
- -
52周最高:
- -
52周最低:
- -
股本:
- -
香港流通股本:
- -
量比:
- -
換手率:
- -
股息:
- -
股息率:
- -
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
市銷率:
- -
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
全球首個cAMP偏向型GLP-1上市!先為達生物改寫賽道格局
格隆汇
·
01/30
先為達生物赴港ipo,五大核心問題待補充説明
中金财经
·
2025/12/15
新股消息 | 先為達生物擬港股上市 中國證監會要求補充説明已實施的股權激勵方案合規性等
智通财经网
·
2025/12/12
先為達生物IPO:累虧超14億核心產品市場競爭激烈 創始人多次減持股份投後估值近50億元
新浪证券
·
2025/10/17
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/91078"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"91078","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91078\",,,,,undefined,":{"symbol":"91078","market":"HK","secType":"STK","nameCN":"杭州先為達生物科技股份有限公司(臨時代碼)","latestPrice":0,"timestamp":1770364800000,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":0,"latestTime":"02-06 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":7,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1770341400000,1770350400000],[1770354000000,1770364800000]],"volumeRatio":0,"lotSize":100,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91078\",,,,,undefined,":{"symbol":"91078","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91078\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91078\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91078\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91078\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607091264","title":"全球首個cAMP偏向型GLP-1上市!先為達生物改寫賽道格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2607091264","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607091264?lang=zh_tw&edition=fundamental","pubTime":"2026-01-30 15:27","pubTimestamp":1769758036,"startTime":"0","endTime":"0","summary":"先颐达®(埃诺格鲁肽注射液)成功获NMPA批准上市,用于成人2型糖尿病患者的血糖控制,成为全球首个获批上市的cAMP偏向型GLP-1受体激动剂。","market":"fut","thumbnail":"https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3726053","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4144","91078","BK4590","GLP"],"gpt_icon":0},{"id":"2591696182","title":"先為達生物赴港ipo,五大核心問題待補充説明","url":"https://stock-news.laohu8.com/highlight/detail?id=2591696182","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591696182?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 10:10","pubTimestamp":1765764601,"startTime":"0","endTime":"0","summary":"览富财经网讯:12月12日,中国证监会公布最新一期《境外发行上市备案补充材料要求》,本周国际司共仅对8家企业出具补充材料要求,其中今年9月19日,向港交所主板递交上市申请书的杭州先为达生物科技股份有限公司-B ,证监会要求其需补充说明五项事项且需律师核查并出具明确的法律意见。据了解,先为达生物是一家接近商业化阶段的生物医药公司,致力于满足体重管理领域 的迫切医疗需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251215/31865199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["91078"],"gpt_icon":0},{"id":"2590050376","title":"新股消息 | 先為達生物擬港股上市 中國證監會要求補充説明已實施的股權激勵方案合規性等","url":"https://stock-news.laohu8.com/highlight/detail?id=2590050376","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590050376?lang=zh_tw&edition=fundamental","pubTime":"2025-12-12 19:32","pubTimestamp":1765539141,"startTime":"0","endTime":"0","summary":"中国证监会国际司共对8家企业出具补充材料要求,其中,要求先为达生物补充说明已实施的股权激励方案合规性等事项。据港交所9月19日披露,先为达生物向港交所主板提交上市申请书,摩根士丹利及中金公司为联席保荐人。公司即将在中国推出埃诺格鲁肽注射液,该产品有望成为全球首款cAMP偏向型GLP-1受体激动剂,用于治疗超重/肥胖症及2型糖尿病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["91078"],"gpt_icon":0},{"id":"2576008513","title":"先為達生物IPO:累虧超14億核心產品市場競爭激烈 創始人多次減持股份投後估值近50億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576008513","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576008513?lang=zh_tw&edition=fundamental","pubTime":"2025-10-17 14:39","pubTimestamp":1760683140,"startTime":"0","endTime":"0","summary":" 近日,杭州先为达生物科技股份有限公司正式向港交所递交主板上市申请。招股书显示,先为达生物成立于2017年,是一家接近商业化阶段的生物医药公司,专注于针对肥胖症及相关疾病的创新体重管理疗法的研发。 这家成立八年的生物医药企业,在腾讯、IDG资本、美团、正心谷资本等知名机构的多轮投资加持下,最新估值已高达49亿元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-10-17/doc-infuetkq8720872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91078"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/91078\",params:#limit:6,delay:false,,,undefined,":[]}}